Nanopharm’s Role in OINDP Bioequivalence & Pharmacokinetics
Explore Nanopharm’s groundbreaking methods in OINDP bioequivalence and pharmacokinetics. Learn how in vitro and in vivo studies are revolutionizing drug development and solubility.
Nanopharm’s Innovations in Nasal Drug Delivery of Biologics
Discover Nanopharm’s pioneering work in nasal drug delivery of biologics. Learn how their research is shaping drug development against SARS-CoV-2.
Nanopharm: cGMP Drug Development in OINDP
Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.
Nanopharm & Leyden – OINDP Intranasal Sprays vs. Respiratory Viruses
Nanopharm & Leyden Labs collaborate on intranasal sprays for broad protection against respiratory viruses. Focused on OINDP drug development.
In Vitro System for Orally Inhaled Drug Release
Discover the development of an in vitro dissolution and release system from Nanopharm for OINDPs (orally inhaled drug products).
Unraveling the Pulmonary Fate of Fluticasone and Friends: Meeting the Physiologic and Pharmacokinetic Challenges
Exploring the role of DPI (Dry powder inhaler) in drug development and the inhalation process and pharmacokinetics of fluticasone propionate.
Elucidating Molecular- and Particle-Level Changes during the Annealing of a Micronized Crystalline Drug
Nanopharm explores annealing in micronized DPIs for drug development. Focus on molecular changes and SFE in Dry Powder Inhaler formulations.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
